TCT 2022 – Edwards tries to Clasp an opportunity

It is close, but is it close enough? Pivotal data on Edwards Lifesciences’ Pascal system, designed to repair faulty mitral valves, showed the device to be non-inferior to Abbott’s money-spinning MitraClip – though it was numerically very slightly worse.

The data, presented on Saturday at the TCT meeting in Boston, were pre-empted by the FDA approving Pascal Precision, which consists of the Pascal and Pascal Ace implants and the catheter used to deliver them. But sellside expectations certainly favour Abbott’s established product. Edwards will have a job competing with a company three times its size.